ProStrakan Group plc develops and commercializes prescription medicines. The company offers its products for women's health, the ageing male, and bone disease therapeutic areas. It offers Adcal for osteoporosis and the correction of calcium deficiency; Adcal D3 for therapeutic supplementation of malnutrition; Alfaprost to treat moderate benign prostatic hypertrophy; AmsaLyo for lymphoblastic and myeloblastic acute leukemia; and Belustine to treat brain tumors, small cell and epidermoid lung cancer, melanomas, Hodgkin's and non-Hodgkin's lymphomas, and myelomas. ProStrakan Group also provides Calci APS to correct calcium and vitamin D deficiency; Ciprofloxacino for bacterial infections of the urinary tract; Dehidrobenzoperidol, Dehydrobenzperidol, Dridol, and Droleptan indications for droperidol; Desuric to treat severe gout; Devogel for the relief of vaginal dryness; Fluconazol Elfar to treat candidiasis; Flutamida Elfar for the palliative treatment of prostatic carcinoma; Hexastat for the second line treatment of ovarian cancer and small cell lung cancer; and Ketensin to treat acute hypertensive episodes. In addition, it offers Meto APS to treat hypertension; Perfane indicated for the short term treatment of acute congestive cardiac failure; Piprol to treat bacterial urinary tract infections; Rectogesic indicated for the relief of chronic anal fissure pain; Simva APS to treat hyper-cholesterolaemia; Sinovial to treat knee arthrosis; and Sufil 500mg to treat helmintiasis. Further, the company provides Tabphyn to treat benign prostatic hyperplasia; Tamoxifeno Elfar for breast cancer; Tebetane Compuesto to treat mild benign prostatic hypertrophy; Tostrex for use in hypogonadal men; and Urinorm to treat severe gout in patients. It sells its products in through its own sales force, bespoke sales teams, and licensing and distribution agreements in Europe and internationally. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.
